Zacks Investment Research on MSN
Why Humana deserves patience now: Too early to buy, too risky to sell
Humana Inc. HUM has tested investor conviction over the past year as rising medical costs, reimbursement uncertainty, and ...
Humana stock has experienced significant fluctuations in recent years, but has historically been able to bounce back after market downturns. However, in 2024, Humana has faced challenges due to rising ...
Humana, the Louisville-based health insurer with an emphasis on Medicare Advantage plans, has announced its new CEO and president will assume the role effective July 1. Previously the company ...
Humana (HUM) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Humana raised its 2025 guidance alongside the release of second quarter results that beat analyst expectations on Wednesday. It’s a bright spot for investors in the health insurance sector following ...
Humana is a private insurance company that offers Medicare Advantage with Part D coverage and stand-alone Part D plans. Deductibles, monthly premiums, and drug copays depend on the specific plan.
Humana trades near fair value, reflecting a mixed profit outlook and Medicare Advantage uncertainties. Click here to read an analysis of HUM stock now.
Wondering if Humana is quietly turning into a value opportunity after a rough stretch, or if the stock is cheap for a reason? Let us break down what the current share price is really telling us. After ...
After consolidating work operations into one downtown office, Humana is permanently closing its Wel at Humana gym. Here's what we know ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results